Related references
Note: Only part of the references are listed.Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer
Kiki M. H. Vangangelt et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Fasting mimicking diet as an adjunct toneoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
Stefanie de Groot et al.
NATURE COMMUNICATIONS (2020)
Does tumor stroma ratio of breast cancer trucut biopsy determine response to neoadjuvant therapy?
Varuna Mallya et al.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY (2020)
The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer
G. W. van Pelt et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2020)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review
C. J. H. Kramer et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit
Pauline E. R. Spronk et al.
EJSO (2019)
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Stefanie de Groot et al.
BREAST CANCER RESEARCH (2019)
Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
Waqar Haque et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients
Kiki M. H. Vangangelt et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations
G. W. van Pelt et al.
VIRCHOWS ARCHIV (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers
Wenyong Tan et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma
K. M. H. Vangangelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study
Toni Roeke et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice
H. Cain et al.
CLINICAL ONCOLOGY (2017)
Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling
S. Goncalves-Ribeiro et al.
ANNALS OF ONCOLOGY (2017)
An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation
Francisco J. Candido dos Reis et al.
BREAST CANCER RESEARCH (2017)
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial
Matthew D. Hale et al.
ONCOTARGET (2016)
Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial
T. J. A. Dekker et al.
MOLECULAR ONCOLOGY (2015)
Microenvironmental regulation of therapeutic response in cancer
Florian Klemm et al.
TRENDS IN CELL BIOLOGY (2015)
Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)
T. J. A. Dekker et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer
Yonghui Wu et al.
GUT (2013)
Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network
Nancy U. Lin et al.
CANCER (2012)
The prognostic value of tumour-stroma ratio in triple-negative breast cancer
A. M. Moorman et al.
EJSO (2012)
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Douglas G. Altman et al.
PLOS MEDICINE (2012)
Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients
Esther M. de Kruijf et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies
Ewout F. W. Courrech Staal et al.
EUROPEAN JOURNAL OF CANCER (2011)
Hallmarks of cancer: Interactions with the tumor stroma
Kristian Pietras et al.
EXPERIMENTAL CELL RESEARCH (2010)
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer
Gordon C. Wishart et al.
BREAST CANCER RESEARCH (2010)
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Pierre Farmer et al.
NATURE MEDICINE (2009)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M. Kaufmann et al.
ANNALS OF ONCOLOGY (2007)
Neoadjuvant chemotherapy for operable breast cancer
J. S. D. Mieog et al.
BRITISH JOURNAL OF SURGERY (2007)
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
KN Ogston et al.
BREAST (2003)
Share Paper
